- Biocept (NASDAQ:BIOC): Q4 GAAP EPS of $0.14 beats by $0.41.
- Revenue of $18.51M (+939.9% Y/Y) beats by $6.19M.
- The company introduced strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system.
- "Our ability to generate higher revenues in recent quarters due to COVID-19 testing significantly reduced our cash burn in 2020, while we continued to provide excellent service for our oncology and COVID-19 customers," President and CEO Michael Nall commented.
- Biocept reported cash and cash equivalents as of Dec. 31, 2020 of $14.4M vs. $9.3M as of Dec. 31, 2019.
- Press Release